A Randomized Phase 2 Study of the Triplet Combination of Ridaforolimus (Rida), Dalotuzumab (Dalo) and Exemestane (Ex) Compared to the Ridaforolimus, Exemestane Doublet in High Proliferation, Estrogen Receptor Positive (Er plus ) Advanced Breast Cancer